image: Tissues where tumor growth is fastest are most affected by drugs, whereas tissues where growth is slow may be tumor sanctuaries. It is these sanctuary sites that are the breeding ground of resistance. view more
Credit: Feng Fu
Tumors acquiring resistance is one of the major barriers to successful cancer therapy. Feng Fu, Sebastian Bonhoeffer (ETH Zurich) and their collaborator Martin Nowak (Harvard) use mathematical models to characterize how important aspects of tumor microenvironment can impair the efficacy of targeted cancer therapies.
Failure of cancer therapy is commonly attributed to pre-existing resistant mutants already present prior to treatment. However, the research publishing this week in PLOS Computational Biology highlights the important role of tumor sanctuaries in the rapid acquisition of resistance.
The authors offer an in silico model for predicting treatment outcomes that depend on the tumor microenvironment within a solid tumor or across metastases. The results show that resistance in non-sanctuary sites is likely originated from sanctuaries with little drug exposure.
There is increasing evidence that the tumor microenvironment influences cell sensitivity to drugs mediating the evolution of drug resistance. The results provide new insights into understanding why cancers tend to quickly become resistant, and that cell migration and the presence of sanctuary sites with little drug exposure are essential to this end.
The researchers say: "In order to improve our ability to fight against cancer, not only we should search for more effective therapies that sufficiently target tumor genetic heterogeneity, but also such efforts will have to be paralleled with finding novel delivery approaches aimed at eliminating potential tumor sanctuaries."
###
Image Caption: Tissues where tumor growth is fastest are most affected by drugs, whereas tissues where growth is slow may be tumor sanctuaries. It is these sanctuary sites that are the breeding ground of resistance.
Image Credit: Feng Fu
Image Link: http://www.plos.org/wp-content/uploads/2015/03/Fu-19-Mar.tif
All works published in PLOS Computational Biology are Open Access, which means that all content is immediately and freely available. Use this URL in your coverage to provide readers access to the paper upon publication: http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1004142
Contact: Feng Fu
Address:
ETH Zurich
Institute for Integrative Biology
Universitätstrasse 16
Zurich, 8092
Switzerland
Phone: +41 44 632 93 03
Email: fufeng@gmail.com
Citation: Fu F, Nowak MA, Bonhoeffer S (2015) Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy. PLoS Comput Biol 11(3): e1004142.doi:10.1371/journal.pcbi.1004142
Funding: The authors gratefully acknowledge the support from the European Research Council
Advanced Grant (PBDR 268540) and the John Templeton Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
About PLOS Computational Biology
PLOS Computational Biology features works of exceptional significance that further our understanding of living systems at all scales through the application of computational methods. All works published in PLOS Computational Biology are Open Access. All content is immediately available and subject only to the condition that the original authorship and source are properly attributed. Copyright is retained. For more information follow @PLOSCompBiol on Twitter or contact ploscompbiol@plos.org.
About PLOS
PLOS is a nonprofit publisher and advocacy organization founded to accelerate progress in science and medicine by leading a transformation in research communication. For more information, visit http://www.plos.org.
Journal
PLoS Computational Biology